November 21st 2024

Publication in Vaccines: Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine

Publication in Vaccines: Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine

Using a pathogenic isolate of SARS-CoV-2, this study shows that a vaccine consisting of capsid virus-like particles (cVLPs) displaying the receptor-binding domain (RBD) of SARS-CoV-2 (Wuhan strain) induces strong neutralizing antibody responses and sterilizing immunity in K18-hACE2 mice; also protecting them from a lethal infection and symptomatic disease, while significantly reducing inflammation and lung pathology associated with severe disease.

To learn more, click here: Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine – PubMed (nih.gov)